Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett(Harvard University), Yves Boucher(Harvard University), Emmanuelle di Tomaso(Harvard University), Dan G. Duda(Harvard University), Lance L. Munn(Harvard University), Ricky T. Tong(Harvard University), Daniel C. Chung(Harvard University), Dushyant V. Sahani(Harvard University), Sanjeeva P. Kalva(Harvard University), Sergey V. Kozin(Harvard University), Mari Mino(Harvard University), Kenneth S. Cohen(Harvard University Press), David T. Scadden(Harvard University Press), Alan C. Hartford(Harvard University), Alan J. Fischman(Harvard University Press), Jeffrey W. Clark(Harvard University Press), David P. Ryan(Harvard University Press), Andrew X. Zhu(Harvard University Press), Lawrence S. Blaszkowsky(Harvard University Press), Helen X Chen(National Institutes of Health), Paul C. Shellito(Harvard University), Gregory Y. Lauwers(Harvard University), Rakesh K Jain(Harvard University)
Nature Medicine
January 25, 2004
10.1038/nm988
Cited by 1,954Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis